| 147.44 -0.01 (-0.01%) | 10-15 14:25 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 182.19 | 1-year : | 212.8 |
| Resists | First : | 155.99 | Second : | 182.19 |
| Pivot price | 146.46  |
|||
| Supports | First : | 144.03 | Second : | 136.63 |
| MAs | MA(5) : | 147.45  |
MA(20) : | 145.16 |
| MA(100) : | 154.18 |
MA(250) : | 160.81 |
|
| MACD | MACD : | 0.7 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 55.4 |
D(3) : | 54.9 |
| RSI | RSI(14): 50.4 |
|||
| 52-week | High : | 194.88 | Low : | 133.69 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MASI ] has closed below upper band by 48.6%. Bollinger Bands are 16.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 151.87 - 152.61 | 152.61 - 153.34 |
| Low: | 143.57 - 144.49 | 144.49 - 145.38 |
| Close: | 145.75 - 147.21 | 147.21 - 148.64 |
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. It offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. It offers connectivity devices; and nasal high flow ventilation and neuromodulation solutions. It provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. The company was incorporated in 1989 and is headquartered in Irvine, California.
Mon, 13 Oct 2025
Masimo Corporation (MASI) Stock Analysis: Exploring a 29.68% Potential Upside in Healthcare Innovation - DirectorsTalk Interviews
Fri, 10 Oct 2025
Masimo (MASI): Evaluating Valuation Following New Evidence of SET Pulse Oximetry Accuracy in Critical Care - simplywall.st
Fri, 10 Oct 2025
Masimo (MASI): Evaluating Valuation Following New Evidence of SET Pulse Oximetry Accuracy in Critical Care - Sahm
Mon, 06 Oct 2025
Masimo Corporation (MASI) Stock Analysis: A 27% Upside Beckons in the Healthcare Sector - DirectorsTalk Interviews
Mon, 06 Oct 2025
Will Upward Analyst Revisions and Earnings Optimism Reshape Masimo’s (MASI) Investment Narrative? - Yahoo Finance
Mon, 29 Sep 2025
Here's How Much $100 Invested In Masimo 10 Years Ago Would Be Worth Today - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 54 (M) |
| Shares Float | 46 (M) |
| Held by Insiders | 5.9 (%) |
| Held by Institutions | 110 (%) |
| Shares Short | 3,810 (K) |
| Shares Short P.Month | 3,540 (K) |
| EPS | -5.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 19.2 |
| Profit Margin | -21.4 % |
| Operating Margin | 17.1 % |
| Return on Assets (ttm) | 1.8 % |
| Return on Equity (ttm) | -22.4 % |
| Qtrly Rev. Growth | 7.9 % |
| Gross Profit (p.s.) | 19.51 |
| Sales Per Share | 39.58 |
| EBITDA (p.s.) | 2.83 |
| Qtrly Earnings Growth | 214.3 % |
| Operating Cash Flow | 177 (M) |
| Levered Free Cash Flow | 93 (M) |
| PE Ratio | -28.82 |
| PEG Ratio | 0 |
| Price to Book value | 7.63 |
| Price to Sales | 3.7 |
| Price to Cash Flow | 45.11 |
| Dividend | 1 |
| Forward Dividend | 0 |
| Dividend Yield | 0.6% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|